Administration of study drugs and follow-up
hypertension
HYPERTENSION
The median (interquartile range [IQR] [25th to 75th percentile]) durations of treatment with the study drug were 336.0 days (300.8–349.3 days) and 336.0 days (315.0–357.0 days) in the azilsartan and candesartan groups, respectively. The numbers of participants whose compliance rate was less than 80% or who suspended the treatment were 5 (5.3%) and 5 (5.3%) in the azilsartan and candesartan groups, respectively. The number of patients who were prescribed additional drugs for HF or hypertension was the same between the two groups (Table Of the 189 participants included in the full analysis set, the average E/e′ ratio using septal and lateral e′ at baseline and 48 weeks of the study analyzed at the core laboratory was obtained from 67 to 69 participants in the azilsartan and candesartan groups, respectively.